GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Other Current Assets

Sinovac Biotech (Sinovac Biotech) Other Current Assets : $17.0 Mil (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Other Current Assets?

Sinovac Biotech's other current assets for the quarter that ended in Jun. 2023 was $17.0 Mil.

Sinovac Biotech's quarterly other current assets declined from Jun. 2022 ($32.5 Mil) to Dec. 2022 ($23.5 Mil) and declined from Dec. 2022 ($23.5 Mil) to Jun. 2023 ($17.0Mil).

Sinovac Biotech's annual other current assets increased from Dec. 2020 ($24.7 Mil) to Dec. 2021 ($171.9 Mil) declined from Dec. 2021 ($171.9 Mil) to Dec. 2022 ($23.5 Mil).


Sinovac Biotech Other Current Assets Historical Data

The historical data trend for Sinovac Biotech's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Other Current Assets Chart

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.54 5.03 24.74 171.89 23.50

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.91 171.89 32.52 23.50 17.05

Sinovac Biotech Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Sinovac Biotech Other Current Assets Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

By Business Wire Business Wire 06-25-2022

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022

SINOVAC to Showcase Products at CPHI Frankfurt

By Business Wire Business Wire 10-28-2022